전신 마취약 시장 규모, 점유율 및 성장 분석 : 약제 유형별, 투여 경로별, 최종 용도별, 적용 분야별, 지역별 - 업계 예측(2026-2033년)

General Anesthesia Drugs Market size was valued at USD 5.79 Billion in 2024 and is poised to grow from USD 5.99 Billion in 2025 to USD 7.89 Billion by 2033, growing at a CAGR of 3.5% during the forecast period (2026-2033).

The general anesthesia drugs market is experiencing significant growth due to the increasing number of surgical procedures and the introduction of innovative anesthetic medications. General anesthesia induces unconsciousness, pain relief, and suppresses autonomic nervous system responses, primarily through intravenous (IV) techniques, which are especially prevalent in cardiovascular and chronic renal procedures. The rise in cosmetic and reconstructive surgeries further amplifies demand, with millions of major surgeries conducted globally each year. New product approvals, like novel local anesthetics and procedural sedation agents, are emerging as lucrative revenue streams for companies in this sector. Thus, the synergy of rising surgical volumes and innovative drug development is expected to propel market expansion in the coming years.

Top-down and bottom-up approaches were used to estimate and validate the size of the General Anesthesia Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

General Anesthesia Drugs Market Segments Analysis

Global General Anesthesia Drugs Market is segmented by drug type, Route of Administration, end-use, application and region. Based on drug type, the market is segmented into propofol, sevoflurane, desflurane, ketamine, thiopental, etomidate and others. Based on route of administration, the market is segmented into intravenous and inhaled. Based on end-use, the market is segmented into hospitals, ambulatory surgical centers, clinics and others. Based on application, the market is segmented into cardiovascular surgery, orthopedic surgery, neurosurgery, general surgery, cosmetic surgery and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the General Anesthesia Drugs Market

The growing prevalence of cancer is significantly driving demand in the General Anesthesia Drugs market. With millions of cancer survivors and an anticipated increase in this population, the need for surgical interventions rises, as these procedures often represent the most effective means of treatment when cancer is detected early. Common cancers like lung, breast, and colorectal cancers necessitate surgeries, which typically require general anesthesia for effective management of pain and anxiety. As more patients undergo operations to address various types of tumors, the reliance on general anesthesia will likely intensify, propelling the market forward as healthcare systems adapt to meet these increasing surgical needs.

Restraints in the General Anesthesia Drugs Market

One significant market restraint in the global general anesthesia drugs market is the increasing prevalence of adverse effects associated with anesthetic agents, which raises safety concerns among healthcare providers and patients alike. Reports of side effects such as respiratory complications, allergic reactions, and postoperative cognitive dysfunction can lead to reluctance in the adoption of these drugs. Regulatory bodies are also imposing stricter guidelines on the usage of certain anesthetics, complicating their approval and market entry. Furthermore, the growing interest in alternative anesthesia methods, including regional anesthesia and sedation, may further limit the market's growth potential as clinicians seek safer and less invasive options.

Market Trends of the General Anesthesia Drugs Market

The general anesthesia drugs market is experiencing significant growth driven by robust research and development efforts aimed at enhancing clinical outcomes and patient recovery. A surge in innovative studies assesses the efficacy of various anesthetics, such as inhaled agents and intravenous options like propofol, leading to improved patient experiences. This heightened focus on optimizing anesthetic protocols reflects a broader trend towards personalized medicine, with stakeholders keen on adapting existing drugs and developing new formulations. Additionally, technological advancements and a growing emphasis on patient safety and comfort further bolster market expansion, establishing a dynamic landscape for anesthesia drug development and application.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Patent Analysis

Global General Anesthesia Drugs Market Size by Drug Type & CAGR (2026-2033)

• Market Overview
• Propofol
• Sevoflurane
• Desflurane
• Ketamine
• Thiopental
• Etomidate
• Others

Global General Anesthesia Drugs Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Intravenous
  • Bolus Injection
  • Continuous Infusion
• Inhaled
  • Volatile Liquids
  • Gases

Global General Anesthesia Drugs Market Size by End-Use & CAGR (2026-2033)

• Market Overview
• Hospitals
• Ambulatory Surgical Centers
• Clinics
• Others

Global General Anesthesia Drugs Market Size by Application & CAGR (2026-2033)

• Market Overview
• Cardiovascular Surgery
• Orthopedic Surgery
• Neurosurgery
• General Surgery
• Cosmetic Surgery
• Others

Global General Anesthesia Drugs Market Size & CAGR (2026-2033)

• North America (Drug Type, Route of Administration, End-Use, Application)
  • US
  • Canada
• Europe (Drug Type, Route of Administration, End-Use, Application)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Type, Route of Administration, End-Use, Application)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Type, Route of Administration, End-Use, Application)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Type, Route of Administration, End-Use, Application)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Baxter International Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fresenius SE & Co. KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• B. Braun Melsungen AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hikma Pharmaceuticals PLC (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Piramal Enterprises Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eisai Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations